Table 3.
Unadjusted predictors for all-cause death of elderly patients
| P value | Hazard ratio | 95 % CI | |
|---|---|---|---|
| Age (years) | 0.068 | 1.073 | 0.995–1.158 |
| Male sex | 0.505 | 0.772 | 0.360–1.654 |
| Obesity | 0.107 | 0.367 | 0.109–1.242 |
| ACS | 0.002 | 3.661 | 1.612–8.316 |
| Prior MI | 0.031 | 2.742 | 1.100–6.836 |
| Prior PCI | 0.882 | 0.896 | 0.211–3.806 |
| Prior CABG | 0.399 | 0.045 | 0.000–61.236 |
| Hypertension | 0.138 | 0.570 | 0.272–1.198 |
| Diabetes mellitus | 0.583 | 1.242 | 0.573–2.692 |
| Dyslipidemia | 0.066 | 0.484 | 0.223–1.050 |
| Hyperuricemia | 0.107 | 1.870 | 0.873–4.004 |
| Cigarette smoking | 0.661 | 0.789 | 0.274–2.275 |
| Family history | 0.768 | 0.835 | 0.252–2.769 |
| eGFR (ml/min/1.73 m2) | 0.005 | 0.972 | 0.953–0.991 |
| Total cholesterol (mg/dl) | 0.035 | 0.986 | 0.973–0.999 |
| LDL cholesterol (mg/dl) | 0.127 | 0.989 | 0.975–1.003 |
| HDL cholesterol (mg/dl) | 0.469 | 0.989 | 0.961–1.018 |
| TG (mg/dl) | 0.053 | 0.990 | 0.980–1.000 |
| Glucose (mg/dl) | 0.024 | 1.006 | 1.001–1.012 |
| HbA1c (%) | 0.742 | 0.936 | 0.634–1.384 |
| LVEF (%) | <0.001 | 0.938 | 0.916–0.961 |
| DAPT | 0.370 | 0.613 | 0.211–1.787 |
| Anticoagulant therapy | 0.087 | 1.199 | 0.359–4.001 |
| Statins | 0.007 | 0.290 | 0.117–0.717 |
| β-Blockers | 0.177 | 0.554 | 0.235–1.307 |
| ACE-Is | 0.663 | 1.243 | 0.466–3.315 |
| ARBs | 0.514 | 0.767 | 0.346–1.700 |
| RAS-Is | 0.837 | 0.925 | 0.440–1.945 |
| CCBs | 0.013 | 0.315 | 0.127–0.781 |
| Vasodilators | 0.719 | 0.871 | 0.412–1.843 |
| Diuretics | 0.043 | 2.321 | 1.026–5.248 |
| Aldosterone antagonist | 0.001 | 4.267 | 1.778–10.238 |
| Antidiabetic drugs | 0.151 | 0.348 | 0.082–1.468 |
| Thiazolidinediones | 0.517 | 0.047 | 0.000–484.579 |
| Insulin | 0.899 | 0.875 | 0.113–6.783 |
| LMT | 0.057 | 2.434 | 0.975–6.075 |
| MVD | 0.728 | 1.157 | 0.508–2.635 |
ACS acute coronary syndrome, Prior MI prior history of myocardial infarction, Prior PCI prior history of percutaneous coronary intervention, Prior CABG prior history of coronary artery bypass graft, eGFR estimated glomerular filtration rate, LDL low-density lipoprotein, HDL high-density lipoprotein, TG triglyceride, LVEF left ventricular ejection fraction, DAPT dual antiplatelet therapy, Statin HMG-CoA inhibitor, ACE-I angiotensin-converting enzyme inhibitor, ARB angiotensin II receptor blocker, RAS-I renin–angiotensin system inhibitor, CCB calcium-channel blocker, LMT left main trunk disease, MVD multivessel disease, CI confidence interval